![]() SciClone Pharmaceuticals SciClone Pharmaceuticals (SciClone) is a global specialty pharmaceutical company with a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. | ![]() Karyopharm Therapeutics Karyopharm Therapeutics is a commercial-stage pharmaceutical company that pioneers in cancer therapies. | ![]() Sol-Gel Technologies Sol-Gel Technologies is engaged in the development of a range of specialty pharmaceuticals. | ||
Founding Date | Founding Date 1895 | Founding Date 1989 | Founding Date 2008 | Founding Date 1997 |
Type | Type Public | Type Private | Type Public | Type Public |
Tags | ||||
Locations | Locations Bad Vilbel, DE HQ Beijing, CN Hangzhou Shi, CN Shanghai, CN Bad Vilbel, DE Budapest, HU Vilnius, LT see more | Locations Foster City, US HQ | Locations Newton, US HQ Givatayim, IL | Locations Ness Ziona, IL HQ |
Employees | Employees 12,33911% increase | Employees 1102% decrease | Employees 22818% decrease | Employees 34 |
Valuation ($) | Valuation ($) 6 b | Valuation ($) N/A | Valuation ($) 111.7 m | Valuation ($) 18 m |
Financial | ||||
Revenue (est.) | Revenue (est.) €3b (FY, 2020) | Revenue (est.) $160.1m (FY, 2016) | Revenue (est.) $146.1m (FY, 2025) | Revenue (est.) $19.4m (FY, 2025) |
Cost of goods | Cost of goods €1.3b (FY, 2020) | Cost of goods N/A | Cost of goods $5.9m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit €1.7b (FY, 2020) | Gross profit N/A | Gross profit $140.1m (FY, 2025) | Gross profit $19.4m (FY, 2025) |
Net income | Net income €181.9m (FY, 2020) | Net income $30.7m (FY, 2016) | Net income ($196m) (FY, 2025) | Net income ($6.1m) (FY, 2025) |

SciClone Pharmaceuticals (SciClone) is a global specialty pharmaceutical company with a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders.
View company
Karyopharm Therapeutics is a commercial-stage pharmaceutical company that pioneers in cancer therapies.
View company
Sol-Gel Technologies is engaged in the development of a range of specialty pharmaceuticals.
View company